You have accessJournal of UrologyKidney Cancer: Basic Research (IV)1 Apr 2013619 ISOLATION AND ANALYSIS OF CIRCULATING TUMOR CELLS IN RENAL CELL CARCINOMA E. Jason Abel, Ben P. Casavant, Jacob T. Tokar, Joshua M. Lang, and David J. Beebe E. Jason AbelE. Jason Abel Madison, WI More articles by this author , Ben P. CasavantBen P. Casavant Madison, WI More articles by this author , Jacob T. TokarJacob T. Tokar Madison, WI More articles by this author , Joshua M. LangJoshua M. Lang Madison, WI More articles by this author , and David J. BeebeDavid J. Beebe Madison, WI More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2013.02.170AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Circulating tumor cells (CTCs) have demonstrated prognostic ability in prostate and breast cancer but similar studies in Renal Cell Carcinoma (RCC) are limited because the current techniques rely on positive selection of cells using cell surface markers rarely expressed in RCC cells. We have designed a novel platform to permit the use of any antibody of interest bound to paramagnetic particles (PMPs) to isolate and purify PMP-bound cells via immiscible oil barriers. The purpose of this study was to demonstrate and validate RCC cell isolation from blood by positive selection of cells expressing carbonic anhydrase nine (CAIX). METHODS The Vertical Immiscible Filtration Assisted by Surface Tension (VerIFAST) platform was designed (BPC, DJB patent filed) using the relative dominance of surface tension in the microscale to create virtual walls between oil and aqueous phases filtering contaminants in a single step, while maintaining cell viability to permit further analysis. Initial experiments used samples of whole blood spiked with known RCC cell lines (786-0). After optimization of technique and confirmation of capture, samples from patients with locally advanced and metastatic RCC were evaluated after IRB approval and patient consent. Captured cells were stained with cytokeratins and Ki-67. RESULTS Initial experiments were designed to optimize CTC capture using anti-CAIX antibodies bound to PMP. A high capture efficiency of the spiked 786-0 cells (>75% capture efficiency) was able to be demonstrated using commercially available antibodies. Within the device, intracellular staining was demonstrated with successful staining of both cytokeratins and the proliferative marker, Ki-67(figure). Likewise, CTCs have been isolated from RCC patient samples using identical technique and staining for intracellular cytokeratins. CONCLUSIONS Isolation and purification of CTC cells from peripheral blood of RCC patients using CAIX is possible using this novel platform. We have demonstrated the ability to perform intracellular analyses, which will be important to study the prognostic value of CTC in RCC. Future studies will focus on nucleic acid isolation to investigate tumor heterogeneity and the role of CTC in cancer progression. © 2013 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 189Issue 4SApril 2013Page: e253 Advertisement Copyright & Permissions© 2013 by American Urological Association Education and Research, Inc.MetricsAuthor Information E. Jason Abel Madison, WI More articles by this author Ben P. Casavant Madison, WI More articles by this author Jacob T. Tokar Madison, WI More articles by this author Joshua M. Lang Madison, WI More articles by this author David J. Beebe Madison, WI More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract